Cellular Biomedicine Group, Inc. provided an overview and update of clinical and pre-clinical programs currently being researched and developed. Immuno-oncology: Anti-BCMA CAR targeting Multiple Myeloma, Anti-CD19/CD20 BiCAR targeting NHL, AFP TCR-T targeting hepatocellular carcinoma, TIL1 (combo w/anti-PD-1) targeting non-small cell lung cance – Pre-clinical and Anti-BCMA CAR, Anti-CD19/CD20 BiCAR, and TCR clinical studies up to date are conducted through IIT. Regenerative - Human Adipose Mesenchymal Progenitor Cells: ReJoin Autologous therapy for Knee Osteoarthritis – Phase II and AlloJoin Allogenic therapy for KOA – Phase II AlloJoin and Re-Join were both approved for Phase 2 clinical trial by the Center for Drug Evaluation in 2019.